Search results
Results from the WOW.Com Content Network
A large-scale study in Buenos Aires from December 29, 2020, to May 15, 2021, with 663,602 participants aged 60 and older who received Spunik V, the Oxford–AstraZeneca vaccine, or the Sinopharm BIBP vaccine observed an overall efficacy of 98% (95% CI, 95 – 99%) against COVID-19-related deaths. The study noted that the three vaccines showed a ...
In the UK, 15,121 health care workers from 104 hospitals who had tested negative for antibodies prior to the study, were followed by RT-PCR tests twice a week from 7 December 2020 to 5 February 2021, a study compared the positive results for the 90.7% vaccinated share of their cohort with the 9.3% unvaccinated share, and found that the Pfizer ...
Pfizer and Moderna vaccines are both safe and have similar effectiveness at preventing COVID-19 illness. Clinical trial data when they were first released in December 2020 showed 95% efficacy for ...
Vaccine Initial effectiveness by severity of COVID-19 Study location Refs Asymptomatic Symptomatic Hospitalization Death Oxford–AstraZeneca
While the efficacy rates were lower than the Pfizer–BioNTech and Moderna vaccines, its single-dose regimen and normal refrigerator storage requirement (2 to 8 °C) could make it a favorable option for many countries. It has similar efficacy to the Janssen vaccine, another one-shot adenovirus vaccine found to be 66% effective in a global trial.
The experimental vaccine, which met the main trial goal, was being tested in more than 11,000 people aged 12 years and older. The shot showed superior efficacy in adults than the current vaccine ...
Retrospective cohort study of the effectiveness of two Russian vaccines against the SARS-CoV-2 Delta variant in Moscow (June–July 2021) proved that EpiVacCorona, unlike Sputnik V, is an ineffective vaccine and therefore cannot protect against COVID-19. [4]
Moderna fell as much as 7% on Friday after Wall Street analysts raised concerns over faster declines in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine when compared ...